Androgen Signaling Pathway in Neurodegeneration

Androgen Signaling Pathway in Neurodegeneration

Introduction

Androgen Signaling Pathway In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

Overview

The androgen signaling pathway encompasses a complex network of hormone-receptor interactions that play critical roles in neuronal survival, cognitive function, and neuroprotection. Androgens, primarily testosterone and dihydrotestosterone (DHT), signal through the androgen receptor (AR) to modulate various cellular processes that become dysregulated in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [1](https://pubmed.ncbi.nlm.nih.gov/23481064/). [@structure2013]

Androgen Receptor Structure and Function

Genomic Structure

The androgen receptor (AR) gene is located on chromosome Xq12 and encodes a 110 kDa protein belonging to the nuclear receptor superfamily of steroid hormone receptors [2](https://pubmed.ncbi.nlm.nih.gov/22399287/). The AR protein consists of several distinct domains: [@sex2009]

...

Androgen Signaling Pathway in Neurodegeneration

Introduction

Androgen Signaling Pathway In Neurodegeneration represents a key pathological mechanism in neurodegenerative diseases. This page explores the molecular and cellular processes involved, their contribution to disease progression, and therapeutic implications.

Overview

The androgen signaling pathway encompasses a complex network of hormone-receptor interactions that play critical roles in neuronal survival, cognitive function, and neuroprotection. Androgens, primarily testosterone and dihydrotestosterone (DHT), signal through the androgen receptor (AR) to modulate various cellular processes that become dysregulated in neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS) [1](https://pubmed.ncbi.nlm.nih.gov/23481064/). [@structure2013]

Androgen Receptor Structure and Function

Genomic Structure

The androgen receptor (AR) gene is located on chromosome Xq12 and encodes a 110 kDa protein belonging to the nuclear receptor superfamily of steroid hormone receptors [2](https://pubmed.ncbi.nlm.nih.gov/22399287/). The AR protein consists of several distinct domains: [@sex2009]

• N-terminal domain (NTD): Contains activation function 1 (AF-1) and mediates transcriptional activation
• DNA-binding domain (DBD): Two zinc finger motifs that bind to androgen response elements (AREs)
• Hinge region: Contains the nuclear localization signal (NLS)
• Ligand-binding domain (LBD): Binds testosterone and DHT with high affinity

Expression in the Brain

Androgen receptors are widely expressed in brain regions critical for cognition and motor control: [@testosterone2009]

• Hippocampus: CA1-CA3 pyramidal neurons, dentate gyrus granule cells
• Cortex: Layer V pyramidal neurons
• Basal ganglia: Striatal medium spiny neurons, substantia nigra pars compacta dopaminergic neurons
• Spinal cord: Motorneurons
• Hypothalamus: neurons, inter Various neuroendocrine populations

Androgen Signaling Mechanisms

Classical Genomic Pathway

Non-Genomic (Rapid) Signaling

Androgens also signal through membrane-associated receptors to elicit rapid cellular responses: [@testosterone2010]

cAMP/PKA pathway: Activation leads to phosphorylation of CREB

PI3K/Akt pathway: Promotes neuronal survival

MAPK/ERK pathway: Regulates synaptic plasticity

Calcium signaling: Modulates neuronal excitability

Androgens in Alzheimer's Disease

Epidemiological Evidence

• Men have a lower incidence of AD compared to women, partly due to protective effects of androgens [3](https://pubmed.ncbi.nlm.nih.gov/19720209/)
• Low testosterone levels correlate with increased AD risk in men [4](https://pubmed.ncbi.nlm.nih.gov/18250098/)
• Testosterone replacement therapy shows promise in improving cognitive function

Molecular Mechanisms in AD

| Mechanism | Effect | References | [@dht2009]
|-----------|--------|------------| [@androgens2008]
| Amyloid-β metabolism | Testosterone reduces Aβ production via BACE1 inhibition | [5](https://pubmed.ncbi.nlm.nih.gov/20629172/) | [@testosterone2012]
| Tau phosphorylation | DHT inhibits GSK3β activity, reducing tau pathology | [6](https://pubmed.ncbi.nlm.nih.gov/19558164/) | [@mitochondrial2014]
| Synaptic plasticity | Androgens enhance LTP and dendritic spine density | [7](https://pubmed.ncbi.nlm.nih.gov/18950697/) | [@testosterone2014]
| Neuroinflammation | Testosterone suppresses microglial activation | [8](https://pubmed.ncbi.nlm.nih.gov/22426079/) | [@testosterone2015]
| Mitochondrial function | AR signaling enhances mitochondrial biogenesis | [9](https://pubmed.ncbi.nlm.nih.gov/25129033/) | [@testosterone2015a]

Androgen-AR Signaling in AD Pathogenesis

The androgen receptor plays complex roles in AD: [@testosterone2012a]

APP processing: AR interacts with APP and influences amyloidogenic processing

Tau pathology: AR signaling modulates tau kinases and phosphatases

Oxidative stress: Androgens upregulate antioxidant enzymes (SOD, catalase)

Autophagy: AR activation promotes clearance of misfolded proteins

Neuroinflammation: Androgens have anti-inflammatory effects on microglia

Androgens in Parkinson's Disease

Clinical Evidence

• Testosterone deficiency is associated with increased PD risk in men [10](https://pubmed.ncbi.nlm.nih.gov/24853686/)
• Motor symptoms in PD correlate with low testosterone levels [11](https://pubmed.ncbi.nlm.nih.gov/25945507/)
• Androgen deprivation therapy (ADT) for prostate cancer increases PD risk

Neuroprotective Mechanisms in PD

Androgens and α-Synuclein

• Testosterone reduces α-synuclein aggregation in vitro [12](https://pubmed.ncbi.nlm.nih.gov/25855009/)
• AR agonists protect dopaminergic neurons from α-syn toxicity
• Low testosterone may contribute to Lewy body formation

Androgens in Amyotrophic Lateral Sclerosis

Evidence from Models

• AR is expressed in spinal motor neurons
• Testosterone has protective effects in SOD1 mouse models [13](https://pubmed.ncbi.nlm.nih.gov/22130063/)
• Gonadectomy accelerates disease in male ALS mice
• Testosterone replacement delays disease progression

Mechanisms in ALS

• Excitotoxicity: Androgens modulate glutamate transporter expression
• Oxidative stress: Testosterone enhances antioxidant defenses
• Mitochondrial dysfunction: AR signaling promotes mitochondrial health
• Neuroinflammation: Androgens suppress astrocyte and microglial activation

Androgen Receptor Dysregulation in Neurodegeneration

AR Polyglutamine (PolyQ) Expansion

• Normal AR contains 10-36 glutamine residues (CAG repeats)
• Spinobulbar muscular atrophy (SBMA): 38-62 CAG repeats causes AR aggregation
• PolyQ-expanded AR forms toxic aggregates in motor neurons
• Similar mechanisms may contribute to sporadic neurodegeneration

AR Post-Translational Modifications

| Modification | Effect in Neurodegeneration | [@testosterone2013]
|--------------|----------------------------|
| Phosphorylation | Alters transcriptional activity, subcellular localization |
| Acetylation | Modulates AR stability and degradation |
| Ubiquitination | Controls AR turnover, aggregation propensity |
| Sumoylation | Influences transcriptional repression |
| Methylation | Affects coactivator recruitment |

AR Fragmentation

• Proteolytic cleavage of AR generates truncated fragments
• AR cleavage products may acquire toxic functions
• Caspase-3 and calpain-mediated cleavage is increased in AD brain

Therapeutic Implications

Androgen Replacement Therapy

Potential Benefits:

• Cognitive improvement in hypogonadal men [14](https://pubmed.ncbi.nlm.nih.gov/23216333/)
• Neuroprotective effects in animal models
• May reduce amyloid burden and tau pathology

Risks and Concerns:

• Prostate cancer progression
• Cardiovascular events
• Potential for AR aggregation with supraphysiological doses
• Conversion to estrogen (aromatization)

Selective Androgen Receptor Modulators (SARMs)

SARMs offer tissue-selective activation:

| Compound | Tissue Specificity | Therapeutic Potential |
|----------|-------------------|----------------------|
| LGD-3303 | Bone, muscle, brain | Neuroprotection |
| S-1 | Muscle, bone | Cognitive benefits |
| Ostarine | Muscle, bone | Motor neuron protection |
| RAD-140 | Muscle, brain | Neuroprotective |

AR-Targeted Strategies

AR agonists: Promote neuroprotective signaling

AR antagonists: May be beneficial in SBMA

Coactivator modulators: Enhance protective transcription

Protein-protein interaction inhibitors: Prevent AR aggregation

Cross-Pathway Interactions

Androgen-Estrogen Interactions

• Aromatase converts testosterone to estradiol
• Both hormones have neuroprotective effects
• Balance between androgen and estrogen signaling is critical
• Estrogen can both complement and antagonize androgen effects

Androgen and Growth Factor Signaling

• Cross-talk with IGF-1 signaling
• Synergistic effects with BDNF
• Interactions with NGF for motor neuron survival

Background

The study of Androgen Signaling Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

• Muñoz P et al. (2026 Mar) [Effects of gonadectomy on brain sex hormone levels and amyloid pathology in male and female App(NL-G-F) and App(NL-F) mice.](https://pubmed.ncbi.nlm.nih.gov/41808585/). J Neuroendocrinol*
• Parkinson H et al. (2026 Feb 5) [Adult and perimenopausal acne and the nurse's role in management.](https://pubmed.ncbi.nlm.nih.gov/41636006/). Br J Nurs*
• Portman N et al. (2026 Jan) [Characterising the effect of circulating sphingolipids on metastatic prostate cancer cells.](https://pubmed.ncbi.nlm.nih.gov/41365058/). EBioMedicine*
• Alhadrami M et al. (2025 Dec 12) [Androgen Effects on Amyloid Precursor Protein Processing Pathways in Cancer: A Systematic Review.](https://pubmed.ncbi.nlm.nih.gov/41614805/). Curr Issues Mol Biol*
• Jeon HY et al. (2025 Dec 11) [BPTF regulates androgen receptor activity by enhancing chromatin accessibility and stabilizing the AR-FOXA1 interaction.](https://pubmed.ncbi.nlm.nih.gov/41381516/). Nat Commun*

See Also

• Testosterone Signaling in Neurodegeneration
• Estrogen Replacement Therapy
• [Neurotrophic Signaling Pathway](/mechanisms/neurotrophic-signaling-pathway)
• [Mitochondrial Dysfunction Pathway](/mechanisms/mitochondrial-dysfunction)

External Links

• [Androgen Receptor Mutations Database](https://androgenrx.mgh.harvard.edu/)
• [Nuclear Receptor Signaling Atlas (NURSA)](https://www.nursa.org/)

Confidence Assessment

🟡 Moderate Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 14 references |
| Replication | 0% |
| Effect Sizes | 25% |
| Contradicting Evidence | 0% |
| Mechanistic Completeness | 75% |

Overall Confidence: 44%

References

[Unknown, Androgen receptor function in the nervous system (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23481064/)

[Unknown, Structure and function of the androgen receptor (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/22399287/)

[Unknown, Sex differences in Alzheimer's disease (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19720209/)

[Unknown, Testosterone and Alzheimer's disease risk (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/18250098/)

[Unknown, Testosterone and amyloid-beta metabolism (2010) (2010)](https://pubmed.ncbi.nlm.nih.gov/20629172/)

[Unknown, DHT and tau phosphorylation (2009) (2009)](https://pubmed.ncbi.nlm.nih.gov/19558164/)

[Unknown, Androgens and synaptic plasticity (2008) (2008)](https://pubmed.ncbi.nlm.nih.gov/18950697/)

[Unknown, Testosterone and neuroinflammation (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22426079/)

[Unknown, AR and mitochondrial biogenesis (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/25129033/)

[Unknown, Testosterone and Parkinson's disease risk (2014) (2014)](https://pubmed.ncbi.nlm.nih.gov/24853686/)

[Unknown, Testosterone and motor symptoms in PD (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25945507/)

[Unknown, Testosterone and alpha-synuclein aggregation (2015) (2015)](https://pubmed.ncbi.nlm.nih.gov/25855009/)

[Unknown, Testosterone in ALS models (2012) (2012)](https://pubmed.ncbi.nlm.nih.gov/22130063/)

[Unknown, Testosterone therapy and cognition (2013) (2013)](https://pubmed.ncbi.nlm.nih.gov/23216333/)